Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides pteronyssinus + dermatophagoides farinae allergen immunotherapy
- Development stage
- Phase 2
- Lead developer
- Asac Pharmaceutical Immunology
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Dermatophagoides pteronyssinus + Dermatophagoides farinae allergen immunotherapy is a sublingual biologic treatment developed by Asac Pharmaceutical Inmunology for the management of house dust mite-induced allergic rhinitis and rhinoconjunctivitis. The therapy consists of a standardized liquid extract containing allergens from the two most common house dust mite species, *D. pteronyssinus* and *D. farinae*. It functions by inducing peripheral T-cell tolerance, promoting a shift from a pro-inflammatory Th2-mediated allergic response to a regulatory T-cell (Treg) and Th1 response. This immunological shift leads to the production of allergen-specific IgG4 'blocking' antibodies and a reduction in IgE-mediated mast cell and basophil degranulation. The product is currently being evaluated in Phase 4 clinical trials to optimize dosing regimens using nasal provocation testing in patients with or without associated mild asthma.
- Other names
- HDM SLITHouse dust mite sublingual immunotherapyD. pteronyssinus + D. farinae SLITASAC Pharma SLITDermatophagoides pteronyssinus + Dermatophagoides farinae allergen immunotherapy
02
Targets
BCR (Immunoglobulin G B Cell Receptor)HDM-specific IgE (House dust mite-specific immunoglobulin E)Allergen-specific T-cell receptors recognizing house dust mite-derived peptide-MHC complexesγδ TCR (T-cell receptor)
Beyond the preview
Go deeper on dermatophagoides pteronyssinus + dermatophagoides farinae allergen immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides pteronyssinus + dermatophagoides farinae allergen immunotherapy.